Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...

AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These ...

Axplora invests $30 million in lyophilization at Le Mans site, boosting ADC production. Facilities enhance control, reliability, and traceability.

General Atlantic, KKR and CVC are among global PE firms evaluating a minority stake in IndiaRF-backed Synthimed, which is ...

MUSCAT, FEB 23As Oman advances its ambitions under Oman Vision 2040, the spotlight is increasingly shifting from mere ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...

Phlow will manufacture epinephrine API in Virginia while Fresenius Kabi formulates and fills finished doses in existing US ...

Delivering Integrated Reaction, Crystallization, Filtration, and Drying Solutions for Advanced Semiconductor Materials ...

The Fine and Specialty Chemicals Market is entering a transformative phase of high-value innovation and application-specific customization, underpinned by specialty chemicals’ critical role as ...

India has emerged as the fastest-growing industrial economy, with global manufacturing output expanding modestly by 0.7 per ...